The analgesic medicine sales in Canada are projected to follow a declining trajectory from 2024 through 2028. Starting at 20.2 USD PPP per capita in 2024, the forecast considers a gradual decrease to 18.5 by 2028. In 2023, sales stood at 20.5 USD PPP per capita. The annual reduction over the forecast period suggests a compound annual growth rate (CAGR) of approximately -1.77%, reflecting a consistent decrease. Year-on-year variations include a steady slump of around 1.98% from 2024 to 2025 and 2025 to 2026, continuing until 2028.

Future trends to watch:

Influence of new healthcare policies that might affect pricing and availability.
Potential shifts in consumer health preferences towards alternative pain management solutions.
Impact of demographic changes on demand for analgesic medications.
Technological advancements in pharmaceuticals that could alter market dynamics.